Assessment of the Symbiotic Fermented Milk in Patients With Irritable Bowel Syndrome

The Effect of a Symbiotic LCA Yoghurt on Health-related Quality of Life and the Symptoms of Irritable Bowel Syndrome in Adults: A Randomized, Double-blind, Placebo Controlled, Multicentre Clinical Trial

This study evaluates the effect of a symbiotic fermented milk on health-related quality of life and irritable bowel syndrome (IBS) symptoms in patients with constipation-predominant IBS.

Study Overview

• Status: Completed
• Conditions: Irritable Bowel Syndrome
• Intervention / Treatment: Other: LCA symbiotic fermented milk; Other: heat-treated fermented milk

Detailed Description

Irritable bowel syndrome (IBS) is one of the most common digestive disorders in the developed world which. It is associated to numerous symptoms, of which the most characteristic are recurrent pain or discomfort in the abdominal region, changes and difficulties related to bowel movements, and bloating. Although not dangerous, the disease may significantly impair the patients' quality of life. Treatment is symptomatic, but currently not very efficient. The use of probiotics in the treatment of IBS is a promising approach and has been the subject of much research in the last two decades.

The purpose of this randomized, placebo-controlled study is to assess changes in health-related quality of life in patients with constipation-predominant IBS after regular consumption of symbiotic fermented milk (containing probiotics and dietary fibres) and to assess its effects on some symptoms, like abdominal pain or discomfort, bloating, and chronic constipation.

• Study Type: Interventional
• Enrollment (Actual): 76
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Confirmed constipation-predominant irritable bowel syndrome (on the basis of Rome III criteria) (≥ 25 % lumpy or hard stools and ≤ 25 % mushy or watery stools).
• Meeting Rome III criteria for the determination of irritable bowel syndrome in the last 6 months prior to inclusion and the presence of symptoms such as abdominal pain, bloating and general digestive discomfort at least twice a week in the last 3 months prior to inclusion.
• Colonoscopy in the last 7 years prior to inclusion with normal results.

Exclusion Criteria:

• Diarrhoea-predominant irritable bowel syndrome (≥ 25 % mushy or watery stools and ≤ 25 % lumpy or hard stools).
• Clinical signs of alarm, such as rectorrhagia, fever, recent unexplained weight loss.
• Organic gastrointestinal diseases, including chronic inflammatory bowel disease and systemic diseases with gastrointestinal difficulties.
• Severe abdominal pain and the taking of analgesics or antispasmodics for the previous 5 days or more.
• Having begun treatment with psychotropic medicines or other drugs for the treatment of irritable bowel syndrome within the previous month.
• Dietary habits that could influence the assessment of the investigational product, such as slimming or a vegetarian diet.
• Known allergy to ingredient(s) in the investigational product.
• Known medical or psycho-physical condition that is, in the opinion of the investigator, in conflict with consumption of the investigational product and/or the course of the study.
• Participation in another clinical study less than one month before inclusion or concurrent participation in another clinical study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Symbiotic; LCA symbiotic fermented milk, 180 g pot, twice daily.	Other: LCA symbiotic fermented milk; LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
Placebo Comparator: Placebo; heat-treated fermented milk, 180 g pot, twice daily.	Other: heat-treated fermented milk; heat-treated fermented milk without probiotic cultures and dietary fibres

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of life	assessed by IBS-QoL questionnaire	4 weeks of product consumption

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvements in IBS symptoms (bloating, abdominal pain, satisfaction with bowel movement, stool frequency and stool consistency)	assessed by IBS - Severity Scoring System	4 weeks of product consumption
Improvements in IBS symptoms (bloating, abdominal pain, satisfaction with bowel movement, stool frequency and stool consistency)	assessed by IBS - Severity Scoring System	2 weeks of product consumption
Quality of life	assessed by IBS-QoL questionnaire	2 weeks of product consumption

Collaborators and Investigators

• Sponsor: Clinres Farmacija d.o.o.
• Collaborators: European Regional Development Fund; Competence Centre for Biotechnology Research and Innovation; Ministry of Education, Science and Sport of the Republic of Slovenia; Institute of Dairy Science and probiotics, Biotechnical Faculty, UL; Dairy Celeia

Study record dates

Study Major Dates

• Study Start: February 1, 2012
• Primary Completion (Actual): January 1, 2013
• Study Completion (Actual): January 1, 2013

Study Registration Dates

• First Submitted: March 12, 2015
• First Submitted That Met QC Criteria: March 12, 2015
• First Posted (Estimate): March 18, 2015

Study Record Updates

• Last Update Posted (Estimate): July 28, 2015
• Last Update Submitted That Met QC Criteria: July 27, 2015
• Last Verified: March 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Disease; Gastrointestinal Diseases; Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Syndrome; Irritable Bowel Syndrome
• Other Study ID Numbers: KC_BRIN